MetaCap

Indaptus Therapeutics (INDP) vs Ovid Therapeutics (OVID)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Ovid Therapeutics (OVID) has outperformed Indaptus Therapeutics (INDP) over the past year, gaining 57.1% versus a gain of 52.4%. Over five years, OVID leads with a -32.5% price change compared with -98.3% for INDP. Indaptus Therapeutics is the larger company by market cap ($433.2 million vs $415.2 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

INDP+52.43%OVID+57.14%
+167%+54%-60%
Nov 21, 20251 yearNov 20, 2026
INDP-98.22%OVID-36.05%
+21%-42%-105%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

INDP versus OVID key metrics
MetricINDPOVID
Share price$2.82$2.20
Market cap$433.16M$415.21M
1-day change-9.90%-5.98%
YTD return-3.09%+34.97%
1-year return+52.43%+57.14%
5-year return-98.26%-32.52%
EPS (TTM)$-3.16$-0.15
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$7.25M
Revenue growth (YoY)—+1181.27%
Net income (latest FY)$-20.85M$-17.41M
Operating margin—-585.20%
Net margin—-240.13%
52-week high$5.96$3.11
52-week low$0.92$1.26
Distance from 52-week high-52.68%-29.15%
Analyst consensus—strong_buy
Avg. price target upside—+179.55%
Average volume712.87K1.98M
Shares outstanding153.60M188.73M
Employees523
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Indaptus Therapeutics

INDP stock →

Indaptus Therapeutics, Inc., a clinical biotechnology company, engages in the development of various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate consists of Decoy20, which is used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, as well as for the treatment of advanced solid tumors.

Health Care · Biotechnology: Pharmaceutical Preparations · 5 employees

About Ovid Therapeutics

OVID stock →

Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of small molecule medicines for brain disorders including epilepsies and seizure-related neurological disorders in the United States. The company is developing OV329, a GABA-AT inhibitor which is in Phase 1 clinical trials for the treatment of adult and infant drug-resistant epilepsies; and OV4071, a first-in-human oral potassium-chloride cotransporter 2 direct activator which is in Phase 1 clinical trials for the treatment of psychosis associated with parkinson's disease, lewy body dementia, and acute schizophrenia.

Health Care · Biotechnology: Pharmaceutical Preparations · 23 employees

INDP vs OVID FAQ

Which is bigger, Indaptus Therapeutics or Ovid Therapeutics?

Indaptus Therapeutics (INDP) is larger, with a market capitalization of $433.16M compared with $415.21M for Ovid Therapeutics (OVID).

Which stock has performed better over the past year, INDP or OVID?

OVID returned +57.14% over the past 12 months, compared with +52.43% for INDP (price return, excluding dividends). Past performance does not predict future results.

Are Indaptus Therapeutics and Ovid Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons